Review Article

Artificial Intelligence in Nephrology: Pioneering Precision with Multimodal Intelligence

Pushkala Jayaraman[1], Ishita Vasudev[2], Akinchan Bhardwaj[3], Girish Nadkarni[1,4], Ankit Sakhuja[1,5], Priti Meena[6]

[1]The Windreich Department of Artificial Intelligence and Human Health, Icahn School of Medicine Mount Sinai, New York, [2]BronxCare Health System Bronx, New York, [3]Fuster Heart Hospital, Icahn School of Medicine Mount Sinai, New York, [4]Division of Nephrology, Mount Sinai, Icahn School of Medicine, Mount Sinai, New York, [5]Institute for Critical Care Medicine Mount Sinai, Icahn School of Medicine, Mount Sinai, New York, USA, [6]Department of Nephrology, All India Institute of Medical Science-Bhubaneswar, Bhubaneswar, Odisha, India

Corresponding author:
Priti Meena, Department of Nephrology, All India Institute of Medical Sciences-Bhubaneswar, Bhubaneswar, Odisha, India.
E-mail: pritimn@gmail.com

Abstract

Artificial intelligence (AI) is a rapidly advancing tool in healthcare, which might have significant implications in nephrology. Integrating AI, particularly through models like GPT-3 and GPT-4, has potential in medical education and diagnostics, achieving accuracy in clinical assessments. AI's ability to analyze large, complex datasets from diverse modalities (electronic health records, imaging, and genetic data) might enable early detection, personalized treatment planning, and clinical decision-making. Key developments include AI-driven chronic kidney disease and acute kidney injury predictive models, which utilize machine learning algorithms to predict risk factors and disease onset, thereby allowing timely intervention. AI is enhancing non-invasive diagnostics like retinal imaging to detect kidney disease biomarkers, offering a promising and cost-effective approach to early disease detection. Despite these advancements, AI implementation in clinical practice faces challenges, including the need for robust data integration, model generalizability across diverse patient populations, and ethical and regulatory standards adherence. Maintaining transparency, explainability, and patient trust is crucial for AI's successful deployment in nephrology. This article explores AI's role in kidney care, covering its diagnostic applications, outcome prediction, and treatment, with references to recent studies that highlight its potential and current limitations.

Keywords: *Algorithms, Artificial intelligence, Critical care, GPT-4, Machine learning, Predictive models*

Introduction

Artificial intelligence (AI) is increasingly being explored for its potential role in modern healthcare. In nephrology, a specialty dealing with complex chronic conditions and acute emergencies, the applicability of AI remains uncertain. While it may offer opportunities to enhance kidney care, its effectiveness in managing intricate clinical, radiological, and pathological data is still under investigation. By leveraging advanced machine learning (ML) algorithms and generative models, AI facilitates multidimensional dataset analysis, providing insights that surpass traditional methodologies. AI applications in nephrology are diverse: chronic kidney disease (CKD), acute kidney injury (AKI), dialysis, kidney transplantation, and histopathology.[1] Predictive algorithms might enable early CKD and AKI detection, enhancing preventive strategies.[2] In dialysis care, researchers have used AI in optimizing treatment regimens and monitoring patient adherence, while in transplantation, it has been tried to aid graft survival prediction and tailoring immunosuppression protocols.[3] In histopathology, AI-powered image analysis systems might increase diagnostic accuracy and identify subtle patterns in renal biopsies that might escape human observation.[4] These tools are invaluable in resource-constrained settings with the unavailability of expert pathologists. By exploring AI's current and potential applications in nephrology, this review discusses its role in advancing precision medicine and improving patient outcomes. The article also emphasizes limitations associated with AI's integration in nephrology.

Concepts of ML, Deep learning (DL), and Natural language processing (NLP)

ML is a subset of AI that entails algorithms capable of learning from data to make predictions or decisions without explicit

How to cite this article: Jayaraman P, Vasudev I, Bhardwaj A, Nadkarni G, Sakhuja A, Meena P. Artificial Intelligence in Nephrology: Pioneering Precision with Multimodal Intelligence. Indian J Nephrol. doi: 10.25259/IJN_496_2024

DOI: 10.25259/IJN_496_2024

Received: 26-08-2024
Accepted: 05-03-2025
Online First: 08-05-2025
Published: ***

programming.[5] It encompasses various techniques, including supervised and unsupervised learning, where models are trained on labeled and unlabeled data, respectively.[6] Additionally, reinforcement learning involves learning optimal actions through trial-and-error interactions with an environment.[7] In nephrology, ML has the potential to analyze large volumes of clinical data to predict disease progression, identify at-risk patients, and recommend personalized treatment plans.[8,9] These models typically utilize various data types, such as patient demographics, laboratory results, and imaging data, to generate prediction models.

DL, an ML subfield, utilizes neural networks with numerous layers to model intricate data connections.[10] It is especially adept at processing unstructured data (e.g., medical images). DL is inspired by the human brain's structure and function, specifically artificial neural networks (ANNs). DL models, often with multiple neuron layers, are exceptional at extracting features from raw data. Convolutional (CNNs) and recurrent neural networks (RNNs) are well-known DL architectures, each designed for specific tasks like image processing and sequential data modeling, respectively. CNNs have been utilized to analyze renal biopsies, identify pathological features, and predict patient outcomes based on imaging data.[11] DL models can also combine multimodal data, such as images, genetic data, and clinical information, to more comprehensively understand a patient's condition.

NLP is a crucial AI technology that focuses on the interaction between computers and human language.[12] It employs ML and DL techniques and linguistic knowledge to enable machines to comprehend, interpret, and generate human language.[13-16] ML is the foundation, DL offers powerful tools for complex data, and NLP applies these tools to the nuanced human language. Refer Figure 1 for AI workflow in Nephrology application.

Current Clinical Practice in Nephrology Using AI/DL

Nephrology education

GPT-4 had shown remarkable potential, outperforming USMLE scores typically earned by early-stage medical students, with valid insights for >84% of responses.[17] These advancements highlight AI's potential to enhance medical education and clinical reasoning, with possible applications in nephrology. Virtual AI-powered environments can provide learning experiences for trainees, simulating complex clinical scenarios like AKI or dialysis complications. Mixed-reality applications such as the CyranoHealth app offer interactive, case-based training tailored to healthcare professionals.[18,19]

Early Diagnosis and Prediction

AI has shown potential in predicting and managing AKI and CKD.[20,21] Various ML models predict adverse outcomes in hospitalized patients at risk of these diseases,



Figure 1: AI workflow in nephrology application. BERT: Bidirectional encoder representations from transformers, CNN: Convolutional neural network, DL: Deep learning, GPT: Generative pre-trained transformers, ML: Machine learning, NLP: Natural language processing, RNN: Recurrent neural network, TF-IDF: Term frequency-inverse document frequency, EHR: Electronic health records, AI: Artificial intelligence.

offering valuable tools for early intervention and resource allocation.[20-25] During the COVID-19 pandemic, the AKI risk in hospitalized patients became a significant concern. To address this, Ponce and colleagues developed a prognostic score using ML techniques.[20] They applied a 10-fold cross-validation method to fit models and validated their accuracy using the Area Under the Receiver Operating Characteristic Curve (AUC ROC). They studied 870 patients from the Latin America AKI COVID-19 Registry and reported a 0.82 AUC ROC, indicating the model's strong predictive ability. Similarly, Vaid and colleagues developed several ML models, including logistic regression, Least Absolute Shrinkage and Selection Operator (LASSO), random forest (RF), and eXtreme Gradient Boosting (XGBoost), to predict the dialysis need or death at various time points after admission of patients with COVID-19 and AKI.[21] LASSO is a regression technique combining variable selection and regularization by shrinking less significant feature coefficients to zero, enhancing model simplicity and interpretability. RF, an ensemble learning method, constructs multiple decision trees (DTs) and aggregates their predictions to improve accuracy and reduce overfitting, making it effective for classification and regression tasks. XGBoost is a highly efficient and powerful gradient boosting algorithm that iteratively improves model accuracy by optimizing weak learners while handling missing data and large datasets with exceptional speed and performance.[13-15] In their multicenter cohort study involving 6093 patients, the XGBoost model without imputation outperformed other models, achieving a 0.85-0.87 AUC ROC and demonstrating AI's effectiveness in predicting critical outcomes in patients with AKI. Another study used DL to identify sub-phenotypes of sepsis-associated AKI in 4001 ICU patients.[22] By analyzing 188 variables, including vital signs and lab results, they identified three unique AKI sub-phenotypes with distinct comorbidities and outcomes. These findings highlight AI's potential in refining AKI classification and guiding personalized treatment strategies. A systematic review on predicting mortality in patients with AKI using AI showed the highest and lowest pooled AUC for the broad learning system model, elastic net final, and the proposed clinical model, respectively.[23] AI can also contribute to the early sepsis diagnosis. A meta-analysis of seven studies demonstrated a 0.89 (95% CI: 0.86–0.92) pooled AUC for ML models predicting sepsis onset 3 to 4 hours in advance, with a 0.81 (95% CI: 0.80–0.81) sensitivity and 0.72 (95% CI: 0.72–0.72) specificity. In comparison, the pooled AUROCs for existing sepsis scoring systems, including the Modified Early Warning System (MEWS), Systemic Inflammatory Response Syndrome (SIRS), and Sequential Organ Failure Assessment (SOFA), were 0.70, 0.50, and 0.78, respectively.[24] These findings suggested that ML models might outperform traditional sepsis scoring systems in predicting sepsis. AI's application in sepsis prediction is still being researched, and the best model type is yet to be formulated. AI has also been applied to CKD management, with several studies backing its potential to enhance early detection and prognosis. For instance, Debal *et al*., explored the capability of different models to predict CKD stages using binary and multi-category approaches.[25] They tested three models: RF, Support Vector Machine (SVM), and DT. SVM is a supervised ML algorithm that identifies an optimal hyperplane to separate data into distinct classes, maximizing the margin for effective classification or regression. DT is a tree-structured algorithm that splits data into branches based on feature values, creating a decision hierarchy to classify data or predict outcomes in an interpretable manner.[5-9] To choose the most important features for these models, they used methods like analysis of variance and recursive feature elimination, combined with cross-validation to improve accuracy. After testing these models with tenfold cross-validation, they found he RF model to outperform SVM and DT, especially when using recursive feature elimination. Tangri and colleagues developed models and equations to predict kidney failure risk by integrating extensive datasets.[26] The meta-analysis included data from 31 cohorts, comprising 721,357 participants with CKD stages 3 to 5 spanning four continents. Using risk factors from the original risk equations, new pooled kidney failure risk equations were developed by calculating and combining cohort-specific hazard ratios. The original equations demonstrated excellent discrimination, effectively distinguishing individuals who developed kidney failure with consistent performance across subgroups by age, race, and diabetes status. Another study showed that an automated, laboratory-based clinical decision support system could enhance physician compliance with guidelines for timely CKD monitoring.[27] An e-technology-based program was designed to identify patients at CKD risk and automatically order relevant screening tests.[28]

AI and Creatinine Clearance

In critically ill patients, creatinine clearance (CrCl) is a key glomerular filtration rate indicator and can fluctuate daily. Huang *et al*. developed and validated predictive models using a gradient-boosting ML algorithm to forecast CrCl one day in advance, leveraging data from 2,825 patients in the EPaNIC multicenter database.[29] Three models were created: the "Core" model, incorporating demographic, admission diagnosis, and daily lab results; the "Core + BGA" model, adding blood gas analysis (BGA) data; and the "Core + BGA + Monitoring" model including high-resolution monitoring data. Model performance was evaluated against the actual CrCl by mean absolute error and root-mean-square error. All models demonstrated higher accuracy and lower prediction errors. Prediction models utilizing routinely collected ICU clinical data accurately predicted next-day CrCL. These models might have applications in adjusting drug dosages and identifying at-risk patients.

Dialysis

Dialysis is characterized by its structured and routine nature and produces lots of patient-specific data, including dialysis prescriptions (e.g., treatment duration, ultrafiltration volumes, and flow rates) and intradialytic biosignals (e.g., blood pressure, heart rate). These datasets, often stored in electronic health records (EHR), are ripe for AI/ML analysis, offering enhanced diagnosis, prognosis, and treatment recommendations. Chan *et al*. employed NLP to extract symptoms from EHRs, achieving higher sensitivity in identifying hemodialysis-related symptoms than traditional coding methods.[30] Zhang *et al*. utilized AI/ML-driven image analysis to classify vascular access aneurysms with impressive accuracy, demonstrating AI's potential in image-based diagnostics.[31] Prognostically, Lee *et al*. developed an RNN model for predicting intradialytic hypotension with high accuracy, showcasing AI's capacity to foresee critical events during dialysis sessions.[32] Accurate dry weight estimation is challenging but essential to reduce morbidity and mortality. Some studies on neural network development showed using bio-impedancemetry, blood volume monitoring, and blood pressure as inputs to predict AI-based dry weight showed that the neural network's predictions outperformed those of experienced nephrologists in most cases, highlighting its potential.[33,34]

Despite these promising developments, routine AI/ML implementation in dialysis remains limited, with only a few such as ML-driven anemia management models, reaching clinical practice.[35]

Vascular access management

AI is now being utilized in vascular access (VA) management through applications in preoperative planning, monitoring, and predictive modeling. The Vexev Ultrasound Imaging System exemplifies advancements in preoperative mapping by employing robotic tomographic ultrasound to provide comprehensive 3-D vascular data comparable to CT or MRI scans without radiation or nephrotoxic contrast agents risks. This hands-free system integrates cloud-based platforms like vxView for remote expert stenosis, aneurysms, and thrombosis analysis.[36] ML can also aid surgical planning, as shown by Doneda *et al*., whose models achieved 96.8% accuracy in predicting arteriovenous fistula (AVF) maturation and postoperative blood flow velocities, optimizing resource utilization, and reducing failure rates.[37] In monitoring and risk prediction, AI-powered tools like DeepVAQ use photoplethysmography (PPG) sensors and DL to assess VA quality with over 92% accuracy, aiding early complication detection.[38] Mel spectrogram analysis, as utilized by Chung *et al*., transforms audio data into visual formats for DL models, successfully predicting AVF stenosis and malfunction with high accuracy.[39] Risk models like PREDICT-AVF and AVF-FM incorporate patient-specific data to forecast complications such as thrombosis and recurrent interventions. The PREDICT-AVF web application, developed using prospective cohort data, achieved a 0.75 AUROC for one-year intervention prediction.[40]

Peritoneal dialysis

AI has now been integrated into the PD care. One example is a chatbot system designed to support PD patients. This system, offers a range of functionalities, including instructional videos, clinical reminders, dietary guidelines, and automatic PD guidance.[41] For clinical predictions, Noh *et al*. utilized ML algorithms to assess mortality risk among 1,730 PD patients, finding that survival-tree models outperformed traditional methods like Cox regression, with a 0.769 concordance index compared to 0.745.[42] Additionally, AI has been applied to predict and manage peritonitis. Zhang *et al*. used a systematic ML approach to analyze immune responses to microbiologically well-defined infections in 83 PD patients presenting with acute peritonitis.[43] Many biomarkers were used to characterize pathogen-specific local immune responses to genera such as *Streptococcus* and coagulase-negative *Staphylococcus* showing value of nonlinear approaches for analyzing complex biomedical datasets where traditional statistical methods fall short and single biomarkers lack sensitivity and specificity. The nature of the immune signatures varied depending on the mathematical model applied. By directly comparing three ML approaches—RF, SVMx, and ANNs—the study identified RF as the most effective model for microbiological and clinical outcome prediction.

Personalized Medicine

The idea "one therapy fits all" is outdated. Precision medicine focuses on optimizing treatment outcomes and minimizing adverse effects for each patient. AI has propelled personalized medicine development. Destere *et al*. demonstrated a forward-backwards ML approach to optimize the early rituximab regimen intensification in patients with membranous nephropathy with high underdosing risk.[44] This method identified the best combination of variables to predict rituximab underdosing using training data and validated these predictions on a test set. CURATE.AI predicts optimal dosages and treatment outcomes based on individual patient data. It continuously adjusts patient profiles as the disease status changes, optimizing dosages for single drugs and drug combinations.[45] IBM Watson for renal oncology uses AI to predict personalized treatment plans and responses.[46]

Kidney imaging

Radiomics involves mathematically extracting quantitative features from medical images.[47] Recent studies use AI, including radiomics-based ML and DL, to derive obscure diagnostic insights through visual inspection of digital images.[48-50] Total kidney volume (TKV) is a crucial imaging marker evaluating Autosomal Dominant Polycystic Kidney Disease (ADPKD) severity and progression. DL networks distinguish renal parenchyma from pathological cysts without manual tracking, estimating TKV as effectively as automated kidney segmentation. Recent studies apply DL algorithms in ultrasound, CT, and MRI to compute TKV in ADPKD patients, matching manual method accuracy.[49-51] Goel *et al*. created a CNN model using 3D-US images to segment PKD regions for TKV computation, achieving a 0.80 Dice score in the test set.[50] (The Dice coefficient is a statistical similarity measure, commonly used to evaluate the overlap between two sets or binary classifications). Li *et al*. conducted a radiomics analysis using diffusion-weighted imaging from fMRI data. The authors developed a logistic regression model to differentiate between individuals with CKD and healthy subjects, achieving 93% sensitivity and 70% specificity.[52]

Kidney Transplantation

AI's application has been researched for pre-transplant evaluation, organ allocation systems, and long-term post-transplant care. Kidney Donor Risk Index, Kidney Donor Profile Index (KDPI), and Estimated Post-Transplant Survival Score tools have enhanced organ allocation by combining donor-recipient data to predict graft survival and optimize matches. Bae *et al*. reported challenges like unchanged discard rates post-KDPI implementation, but newer AI-driven models like neural networks have demonstrated superior predictive accuracy in post-transplant outcomes, including graft survival and delayed graft function (DGF).[53] For instance, Kawakita *et al*. highlighted ML model's advanced performance in predicting DGF, which can improve decision-making and resource allocation.[54] Advanced DL systems, such as those developed by Marsh *et al*., have reduced unnecessary organ discards by enhancing pre-operative graft biopsy analysis.[55] AI has also been used for waitlist management, patient education, and post-transplant monitoring. Tools like ML-based waitlist prediction models and risk stratification algorithms, as described by Pineda *et al*., might help refinine patient care strategies.[56] Pineda *et al*.[56] identified gene signatures associated with rejection utilizing the ML model. In post-transplant settings, AI helped predict complications like pneumonia and cytomegalovirus infection, as shown by Luo *et al*. and Sheppard *et al*., respectively.[57,58] AI-powered surgical systems can also enhance precision through augmented reality and robotic assistance, while personalized immunosuppressive protocols optimize Tacrolimus and Mycophenolate Mofetil (MMF) dosing, demonstrated in studies leveraging genetic polymorphisms and neural networks.[59] As the field advances, AI integration with regenerative medicine and machine perfusion may redefine KT processes, ensuring equitable organ allocation and improving global transplant success rates.

Kidney histopathology

Kidney biopsy pathology is the gold standard in diagnosing kidney parenchymal diseases. However, more standardization in the diagnostic approach is needed. Variability in specimen preparation and pathological examination among observers pose challenges for reproducibility, affecting diagnosis accuracy. AI has seen notable advancements in this field. Whole-slide images (WSIs) are produced through high-throughput slide digitization, enabling efficient utilization of computer-assisted histopathological analysis.[60] Pathology image segmentation with DL involves data preparation, image preprocessing (including normalization and augmentation), model selection and construction (software choice, model training), post-processing techniques application, feature extraction, and correlating these features with diseases.[60-64] Recently, DL algorithms have shown promise in pathology image analysis, including tumor region identification and metastasis detection.[61] Jayapandian *et al*. developed a DL method for segmenting renal cortex tissue structures across various stains (HE, PAS, silver, trichrome). They indicated PAS-stained whole slide images (WSIs) as optimal for achieving consistent segmentation of diverse structures, including glomerular tufts, Bowman's capsules, tubules, peritubular capillaries, arteries, and arterioles.[4] Zeng *et al*. developed DLV algorithms to detect glomerular lesions and classify and quantify various intrinsic glomerular cell types. Additionally, they devised a network-driven mesangial hypercellularity score using PAS-stained slides in 400 Chinese patients diagnosed with immunoglobulin A nephropathy (IgAN).[62] Weis *et al*. showed that DL algorithms, particularly CNN, can accurately identify subtle and overlapping glomerular morphological changes from conventional microscopy. By categorizing nine glomerular alteration classes and training CNNs on datasets curated by nephropathology experts (23,395 images), the models achieved excellent classification performance.[63]

Clinical trials

AI is increasingly integrating into research and development, fueled by advancements in computational technology. Its utility includes analyzing biometric data, imaging, and facilitating trial design, recruitment, retention, and outcome analysis.[64,65] AI-powered tools can streamline protocol drafting using large language models (LLMs) like retrieval-augmented generation (RAG). These tools integrate external knowledge sources, such as KDIGO guidelines, to generate contextually relevant trial documents. However, human oversight remains essential to ensure logical accuracy and precision. AI can potentially enhance patient recruitment by analyzing EHRs and leveraging tools like Criteria2Query for clinical trial eligibility query generation.[66] ML models can further optimize recruitment by managing missing data and identifying high-risk patients, especially in trials on progressive kidney diseases. In pretrial stages, digital twins, such as TWIN-GPT, can enable virtual simulations of patient trajectories.[67] This approach can help in predicting outcomes and adverse events, advancing drug development and hypothesis testing without direct patient involvement. During the consent process, AI-driven chatbots can be used to simplify documentation and improve patient comprehension, though concerns about dehumanization persist. Additionally, real-time AI-driven data analysis can enable dynamic trial adjustments, ensuring timely outcomes. Table 1 and Figure 2 show the overview of AI applications in Nephrology.

Table 1: Overview of applications of AI in Nephrology

Area	Applications	AI Techniques	Benefits	References
Nephrology education	Simulated training for nephrology trainees using AI-powered environments. Enhancing clinical reasoning through virtual scenarios (e.g., AKI or dialysis complications).	Natural Language Processing (NLP), Mixed Reality Platforms.	Improves understanding of complex cases. Bridges knowledge gaps in nephrology trainees. Cost-effective training without patient risk.	18,19
Early diagnosis & prediction	Predicting CKD and AKI risk in hospitalized patients. AI-driven prognostic scores for AKI outcomes. Aki subphenotyping of AKI and sepsis-related kidney injury for personalized treatments.	ML, Gradient Boosting Models, Support Vector Machines (SVMs), Deep Learning (DL).	Enables early intervention. Enhances resource allocation. Reduces disease burden through timely treatment.	20-21
Dialysis	Monitoring intradialytic parameters (e.g., blood pressure, heart rate, laboratory parameters). Predicting intradialytic complications like hypotension. Estimating optimal dry weight using neural networks. AI-based anemia management models for personalized care.	RNN, Neural Networks, Image Analysis, NLP.	Reduces dialysis-associated complications. Improves treatment precision and patient outcomes. Provides actionable insights from biosignal data.	30-33
Kidney transplantation	Predicting graft survival and delayed graft function. AI-enhanced organ allocation through tools like KDPI. AI for patient education and personalized immunosuppression protocols. Post-transplant monitoring for infections and complications.	Neural Networks, ML, DL, Augmented Reality Systems.	Increases transplant success rates. Improves organ allocation accuracy. Enhances patient follow-up and reduces rejection risks.	53-59
Histopathology	Automating renal biopsy analysis. Identifying glomerular lesions and cell types Detecting morphological changes in glomeruli for disease categorization.	DL (e.g., CNN), Whole Slide Image (WSI) Analysis.	Reduces pathologist workload in resource-constrained settings. Enhances diagnostic accuracy and reproducibility. Identifies subtle morphological changes missed in manual evaluations.	60-63
Vascular access management	Preoperative mapping for vascular access using Robotic Tomographic Ultrasound. Predicting vascular access complications like stenosis or thrombosis. Real-time monitoring of vascular access quality.	PPG, ML, DL.	Reduces vascular access failure rates. Enhances long-term viability of AVF. Supports early detection of complications.	36-40
Peritoneal dialysis	Developing chatbots for PD patient support (dietary guidelines, clinical reminders). Predicting peritonitis risk using immune response profiling. Mortality risk assessment for PD patients.	Chatbots, RF, SVM, ANN.	Supports patient self-management. Identifies and mitigates complications early.	41-43
Imaging	Automated segmentation of kidneys and cysts in cystic kidney diseases. Radiomics-based analysis for CKD diagnosis. Calculating TKV in PKD patients.	Radiomics, DL, CNNs.	Improves imaging accuracy. Offers non-invasive, quantitative analysis of kidney diseases. Enhances disease monitoring and progression tracking.	47-52

Contd.,

Table 1: Continued

Personalized Medicine	Optimizing drug dosages for specific patients (e.g., Rituximab dosing in membranous nephropathy). CURATE.AI for real-time therapy adjustments based on patient data. Predicting treatment responses in renal oncology.	ML, CURATE. AI, Genetic Data Integration.	Reduces adverse drug reactions. Tailors treatment to individual patient needs.	44-46
Clinical trials	AI-aided patient recruitment and retention. Developing virtual patient twins for pre-trial simulations. Real-time trial adjustments using AI-driven analytics.	LLMs, RAG, Digital Twins.	Accelerates drug development. Enhances trial inclusivity. Improves the reliability of trial outcomes through dynamic data analysis.	64-67

AKI: Acute kidney injury, CKD: Chronic kidney disease, ML: Machine learning, RNN: Recurrent neural networks, KDPI: Kidney donor profile index, PPG: Photoplethysmography, DL: Deep learning, AVF: Arterio venus fistula, RF: Random forest, SVM: Support vector machines, ANN: Artificial neural networks, PD: Peritoneal dialysis, TKV: Total kidney volume, LLM: Large language models, RAG: Retrieval-augmented generation



Figure 2: Application of AI in Nephrology. AI: Artificial intelligence.

Challenges in Implementing AI in Precision Medicine

Implementing AI in nephrology encounters hurdles such as regulatory barriers, data biases, and the requirement for large, high-quality datasets. Challenges include integrating data from diverse sources, ensuring model applicability across different patient groups, and addressing ethical concerns in clinical settings.[68] Concerns about human oversight to prevent errors, maintain patient trust, and ensure legal accountability for AI-driven decisions also persist.[69]

Explainability and Interpretability in Clinical AI - As ML algorithms play an increasing role in analysis and diagnosis, it's critical to understand how they analyze and interpret data to ensure valid conclusions. Interpretability focuses on grasping the model's overall behavior and cause-effect relationships, identifying issues, and predicting input and parameter change outcomes. Furthermore, the General Data Protection Regulation (GDPR), a European legislative framework, sets forth legal requirements for handling health data, including its acquisition, storage, transfer, processing, and analysis.[70] There is an ongoing need for transparency in the decision-making processes of AI, algorithms interpretability, and ethical implications of integrating these automated systems into clinical settings.[71] Adopting best AI model deployments is essential for assessing their impact in healthcare settings. This includes establishing a learning health system, standardizing EHRs, and ensuring precise data curation. Ensuring legal compliance and data privacy, maintaining high-quality data, and overcoming technical and resource challenges are imperative for successful integration.

Addressing Bias in AI Models

Bias in AI can severely affect the accuracy and fairness of clinical decisions.[70,72,73] Types of bias include:

- Selection Bias: When training data does not represent the general patient population.

- Measurement Bias: Due to inconsistencies in data collection methods across facilities.
- Algorithmic Bias: When the training data or algorithm processing introduces bias.
- Confirmation Bias: When data confirming pre-existing beliefs is prioritized.
- Cultural Bias: When models do not account for cultural differences.

Diversifying data collection, standardizing measurements, using bias detection and mitigation tools, and continuously monitoring model performance can help tackle data bias. Effective AI implementation includes continuous learning from new data, active bias evaluation, model interpretability and explainability workflows, clinician input feedback loops, and fostering multidisciplinary collaboration to ensure clinical relevance and technical reliability.

AI's integration in nephrology stands to transform the field by boosting diagnostic precision, enabling tailored treatment plans, and optimizing clinical workflows. With the capacity to analyze complex datasets—such as EHRS, imaging, and genetic information—AI might empower earlier detection and kidney disease intervention, leading to better patient outcomes. Ensuring patient trust through transparency, explainability, and ethical AI practices remains essential. As AI technologies continue to evolve, robust clinical validation and interdisciplinary collaboration will play pivotal roles in unlocking its full potential in nephrology. Addressing existing challenges and creating a supportive regulatory framework will be key to establishing AI as a more efficient, equitable, and advanced healthcare system cornerstone.

Conflicts of interest: There are no conflicts of interest.

References

1. Ennis J, Gillen D, Rubenstein A, Worcester E, Brecher ME, Asplin J, *et al*. Clinical decision support improves physician guideline adherence for laboratory monitoring of chronic kidney disease: a matched cohort study. BMC Nephrol. 2015;16:163.
2. Farrell D, Chan L. Application of natural language processing in nephrology research. Clin. J. Am. Soc. Nephrol. 2023;18:806-8.
3. Bajaj T, Koyner JL. Artificial intelligence in acute kidney injury prediction. Adv. Chronic Kidney Dis. 2022;29:450-6.
4. Jayapandian CP, Chen Y, Janowczyk AR, Palmer MB, Cassol CA, Sekulic M, *et al*. Development and evaluation of deep learning-based segmentation of histologic structures in the kidney cortex with multiple histologic stains. Kidney Int. 2021;99:86-101.
5. Kung TH, Cheatham M, Medenilla A, Sillos C, De Leon L, Elepaño C, *et al*. Performance of chatGPT on USMLE: Potential for AI-assisted medical education using large language models. PLOS Digit Health 2023;2:e0000198.
6. Strong E, DiGiammarino A, Weng Y, Kumar A, Hosamani P, Hom J, *et al*. Chatbot vs medical student performance on free-response clinical reasoning examinations. JAMA Intern Med 2023;183:1028-30.
7. Santos, E., Castillo, V. Apple vision pro: Comments in healthcare. Human-Computer Interaction 2024;arXiv:2401.08685. Available from: https://doi.org/10.48550/ARXIV.2401.08685.
8. Gellert GA, Rasławska-Socha J, Marcjasz N, Price T, Heyduk A, Mlodawska A, *et al*. The role of virtual triage in improving clinician experience and satisfaction: A narrative review. Telemed Rep 2023;4:180-91.
9. Badillo S, Banfai B, Birzele F, Davydov II, Hutchinson L, Kam-Thong T, *et al*. An introduction to machine learning. Clin. Pharmacol. Ther. 2020;107:871-85.
10. Sarker IH. Machine learning: Algorithms, real-world applications and research directions. SN Comput Sci 2021;2:160.
11. Matsuo Y, LeCun Y, Sahani M, Precup D, Silver D, Sugiyama M, *et al*. Deep learning, reinforcement learning, and world models. Neural Netw. 2022;152:267-75.
12. Shickel B, Bihorac A. The dawn of multimodal artificial intelligence in nephrology. Nat. Rev. Nephrol. 2024;20:79-80.
13. Glassock RJ. Artificial intelligence in medicine and nephrology: Hope, hype, and reality. Clin Kidney J 2024;17:sfae074.
14. Kufel J, Bargieł-Łączek K, Kocot S, Koźlik M, Bartnikowska W, Janik M, *et al*. What is machine learning, artificial neural networks and deep learning?-examples of practical applications in medicine. Diagnostics (Basel) 2023;13:2582.
15. Feng C, Liu F. Artificial intelligence in renal pathology: Current status and future. Biomol Biomed 2023;23:225-34.
16. Buchlak QD, Esmaili N, Bennett C, Farrokhi F. Natural language processing applications in the clinical neurosciences: A machine learning augmented systematic review. Acta Neurochir. Suppl. 2022;134:277-89.
17. Tyagi N, Bhushan B. Demystifying the role of natural language processing (NLP) in smart city applications: Background, motivation, recent advances, and future research directions. Wirel Pers Commun 2023;130:857-908.
18. Chan L, Beers K, Yau AA, Chauhan K, Duffy Á, Chaudhary K, *et al*. Natural language processing of electronic health records is superior to billing codes to identify symptom burden in hemodialysis patients. Kidney Int. 2020;97:383-92.
19. Sheikhalishahi S, Miotto R, Dudley JT, Lavelli A, Rinaldi F, Osmani V. Natural language processing of clinical notes on chronic diseases: Systematic review. JMIR Med Inform 2019;7:e12239.
20. Ponce D, de Andrade LísGM, Claure-Del Granado R, Ferreiro-Fuentes A, Lombardi R. Development of a prediction score for in-hospital mortality in COVID-19 patients with acute kidney injury: A machine learning approach. Sci. Rep. 2021;11.
21. Vaid A, Chan L, Chaudhary K, Jaladanki SK, Paranjpe I, Russak A, *et al*. Predictive approaches for acute dialysis requirement and death in COVID-19. Clin. J. Am. Soc. Nephrol. 2021;16:1158-6.
22. Chaudhary K, Vaid A, Duffy Á, Paranjpe I, Jaladanki S, Paranjpe M, *et al*. Utilization of deep learning for subphenotype identification in sepsis-associated acute kidney injury. Clin. J. Am. Soc. Nephrol. 2020;15:1557-65.
23. Raina R, Shah R, Nemer P, Fehlmen J, Nemer L, Murra A, *et al*. Using artificial intelligence to predict mortality in AKI patients: A systematic review/meta-analysis. Clin Kidney J 2024;17.
24. Islam MM, Nasrin T, Walther BA, Wu CC, Yang HC, Li YC. Prediction of sepsis patients using machine learning approach: A meta-analysis. Comput. Methods Programs Biomed. 2019;170:1-9.
25. Debal DA, Sitote TM. Chronic kidney disease prediction using machine learning techniques. J Big Data 2022;9.
26. Tangri N, Grams ME, Levey AS, Coresh J, Appel LJ, Astor BC, *et al*. Multinational assessment of accuracy of equations for predicting risk of kidney failure: A meta-analysis. JAMA 2016;315:164-74.
27. Ennis J, Gillen D, Rubenstein A, Worcester E, Brecher ME, Asplin J, *et al*. Clinical decision support improves physician guideline adherence for laboratory monitoring of chronic kidney disease: A matched cohort study. BMC Nephrol. 2015;16.

28. Pefanis A, Botlero R, Langham RG, Nelson CL. eMAP:CKD: Electronic diagnosis and management assistance to primary care in chronic kidney disease. Nephrol. Dial. Transplant. 2018;33:121-8.
29. Huang CY, Güiza F, Wouters P, Mebis L, Carra G, Gunst J, *et al*. Development and validation of the creatinine clearance predictor machine learning models in critically ill adults. Crit. Care 2023;27:272.
30. Chan L, Beers K, Yau AA, Chauhan K, Duffy Á, Chaudhary K, *et al*. Natural language processing of electronic health records is superior to billing codes to identify symptom burden in hemodialysis patients. Kidney Int. 2020;97:383-92.
31. Zhang H, Preddie D, Krackov W, Sor M, Waguespack P, Kuang Z, *et al*. Deep learning to classify arteriovenous access aneurysms in hemodialysis patients. Clin Kidney J 2021;15:829-30.
32. Lee H, Yun D, Yoo J, Yoo K, Kim YC, Kim DK, *et al*. Deep learning model for real-time prediction of intradialytic hypotension. Clin. J. Am. Soc. Nephrol. 2021;16:396-40.
33. Niel O, Bastard P, Boussard C, Hogan J, Kwon T, Deschênes G. Artificial intelligence outperforms experienced nephrologists to assess dry weight in pediatric patients on chronic hemodialysis. Pediatr. Nephrol. 2018;33:1799-803.
34. Chiu JS, Chong CF, Lin YF, Wu CC, Wang YF, Li YC. Applying an artificial neural network to predict total body water in hemodialysis patients. Am. J. Nephrol. 2005;25:507-13.
35. Barbieri C, Mari F, Stopper A, Gatti E, Escandell-Montero P, Martínez-Martínez JM, *et al*. A new machine learning approach for predicting the response to anemia treatment in a large cohort of end stage renal disease patients undergoing dialysis. Comput. Biol. Med. 2015;61:56-61.
36. Carroll J, Colley E, Cartmill M, Thomas SD. Robotic tomographic ultrasound and artificial intelligence for management of haemodialysis arteriovenous fistulae. J. Vasc. Access 2025;26:242-50.
37. Doneda M, Poloni S, Bozzetto M, Remuzzi A, Lanzarone E. Surgical planning of arteriovenous fistulae in routine clinical practice: A machine learning predictive tool. J. Vasc. Access 2024;25:1170-9.
38. Julkaew S, Wongsirichot T, Damkliang K, Sangthawan P. DeepVAQ : An adaptive deep learning for prediction of vascular access quality in hemodialysis patients. BMC Med. Inform. Decis. Mak. 2024;24.
39. Chung TL, Liu YH, Wu PY, Huang JC, Tsai YC, Wang YC, *et al*. Prediction of arteriovenous access dysfunction by mel spectrogram-based deep learning model. Int. J. Med. Sci. 2024;21:2252-60.
40. Heindel P, Dey T, Fitzgibbon JJ, Mamdani M, Hentschel DM, Belkin M, *et al*. Predicting recurrent interventions after radiocephalic arteriovenous fistula creation with machine learning and the PREDICT-AVF web app. J. Vasc. Access 2025;26:202-10.
41. Cheng CI, Lin WJ, Liu HT, Chen YT, Chiang CK, Hung KY. Implementation of artificial intelligence chatbot in peritoneal dialysis nursing care: Experience from a Taiwan medical center. Nephrology (Carlton) 2023;28:655-62.
42. Noh J, Yoo KD, Bae W, Lee SJ, Kim K, Cho JH, *et al*. Prediction of the mortality risk in peritoneal dialysis patients using machine learning models: A nation-wide prospective cohort in Korea. Sci Rep 2020;10:7470.
43. Zhang J, Friberg IM, Kift-Morgan A, Parekh G, Morgan MP, Liuzzi AR, *et al*. Machine-learning algorithms define pathogen-specific local immune fingerprints in peritoneal dialysis patients with bacterial infections. Kidney Int. 2017;92:179-91.
44. Destere A, Teisseyre M, Merino D, Cremoni M, Gérard AO, Crepin T, *et al*. Optimization of rituximab therapy in adult patients with PLA2R1-associated membranous nephropathy with artificial intelligence. Kidney Int Rep 2023;9:134-4.
45. Blasiak A, Khong J, Kee T. CURATE.AI: Optimizing personalized medicine with artificial intelligence. SLAS Technol 2020;25:95-105.
46. Jie Z, Zhiying Z, Li L. A meta-analysis of watson for oncology in clinical application. Sci. Rep. 2021;11:5792.
47. Majumder S, Katz S, Kontos D, Roshkovan L. State of the art: Radiomics and radiomics-related artificial intelligence on the road to clinical translation. BJR Open 2023;6:tzad004.
48. Jagtap JM, Gregory AV, Homes HL, Wright DE, Edwards ME, Akkus Z, *et al*. Automated measurement of total kidney volume from 3D ultrasound images of patients affected by polycystic kidney disease and comparison to MR measurements. Abdom Radiol (NY) 2022;47:2408-19.
49. Daniel AJ, Buchanan CE, Allcock T, Scerri D, Cox EF, Prestwich BL, *et al*. Automated renal segmentation in healthy and chronic kidney disease subjects using a convolutional neural network. Magn. Reson. Med. 2021;86:1125-36.
50. Goel A, Shih G, Riyahi S, Jeph S, Dev H, Hu R, *et al*. Deployed deep learning kidney segmentation for polycystic kidney disease MRI. Radiol Artif Intell 2022;4:e210205.
51. Kim Y, Tao C, Kim H, Oh GY, Ko J, Bae KT. A deep learning approach for automated segmentation of kidneys and exophytic cysts in individuals with autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 2022;33:1581-9.
52. Li LP, Leidner AS, Wilt E, Mikheev A, Rusinek H, Sprague SM, *et al*. Radiomics-based image phenotyping of kidney apparent diffusion coefficient maps: Preliminary feasibility & Efficacy. J Clin Med 2022;11:1972.
53. Bae S, Massie AB, Luo X, Anjum S, Desai NM, Segev DL. Changes in discard rate after the introduction of the kidney donor profile index (KDPI). Am. J. Transplant. 2016;16:2202-7.
54. Kawakita S, Beaumont JL, Jucaud V, Everly MJ. Personalized prediction of delayed graft function for recipients of deceased donor kidney transplants with machine learning. Sci. Rep. 2020;10:18409.
55. Marsh JN, Liu TC, Wilson PC, Swamidass SJ, Gaut JP. Development and validation of a deep learning model to quantify glomerulosclerosis in kidney biopsy specimens. JAMA Netw Open 2021;4:e2030939.
56. Pineda S, Sur S, Sigdel T, Nguyen M, Crespo E, Torija A, *et al*. Peripheral blood RNA sequencing unravels a differential signature of coding and noncoding genes by types of kidney allograft rejection. Kidney Int Rep 2020;5:1706-21.
57. Luo Y, Tang Z, Hu X, Lu S, Miao B, Hong S, *et al*. Machine learning for the prediction of severe pneumonia during posttransplant hospitalization in recipients of a deceased-donor kidney transplant. Ann Transl Med 2020;8:82.
58. Sheppard D, McPhee D, Darke C, Shrethra B, Moore R, Jurewitz A, *et al*. Predicting cytomegalovirus disease after renal transplantation: An artificial neural network approach. Int. J. Med. Inform. 1999;54:55-76.
59. Woillard JB, Labriffe M, Debord J, Marquet P. Mycophenolic acid exposure prediction using machine learning. Clin. Pharmacol. Ther. 2021;110:370-9.
60. Wang S, Yang DM, Rong R, Zhan X, Xiao G. Pathology image analysis using segmentation deep learning algorithms. Am. J. Pathol. 2019;189:1686-98.

61. Rudie JD, Rauschecker AM, Bryan RN, Davatzikos C, Mohan S. Applications of artificial intelligence in neuro-oncology. Radiology 2019;290:607-18.
62. Zeng C, Nan Y, Xu F, Lei Q, Li F, Chen T, *et al*. Identification of glomerular lesions and intrinsic glomerular cell types in kidney diseases via deep learning. J. Pathol. 2020;252:53-64.
63. Weis CA, Bindzus JN, Voigt J, Runz M, Hertjens S, Gaida MM, *et al*. Assessment of glomerular morphological patterns by deep learning algorithms. J. Nephrol. 2022;35:417-2.
64. Chan L, Nadkarni GN. The role of artificial intelligence in nephrology clinical trials. J. Am. Soc. Nephrol. 2024;35:1771-3.
65. Lu X, Yang C, Liang L, Hu G, Zhong Z, *et al*. Artificial intelligence for optimizing recruitment and retention in clinical trials: A scoping review. J Am Med Inform Assoc 2024;31:2749-5.
66. Park J, Fang Y, Ta C, Zhang G, Idnay B, Chen F, *et al*. Criteria2Query 3.0: Leveraging generative large language models for clinical trial eligibility query generation. J. Biomed. Inform. 2024;154:104649.
67. Vallée A. Digital twin for healthcare systems. Front Digit Health 2023;5:1253050.
68. Al Kuwaiti A, Nazer K, Al-Reedy A, Al-Shehri S, Al-Muhanna A, Subbarayalu AV, *et al*. A review of the role of artificial intelligence in healthcare. J Pers Med 2023;13:951.
69. Jiang L, Wu Z, Xu X, Zhan Y, Jin X, Wang L, et al. Opportunities and challenges of artificial intelligence in the medical field: Current application, emerging problems, and problem-solving strategies. J. Int. Med. Res. 2021;49:3000605211000157.
70. Yuan B, Li J. The policy effect of the general data protection regulation (GDPR) on the digital public health sector in the European union: An empirical investigation. Int. J. Environ. Res. Public Health 2019;16:1070.
71. Naik N, Hameed BMZ, Shetty DK, Swain D, Shah M, Paul R, *et al*. Legal and ethical consideration in artificial intelligence in healthcare: Who takes responsibility?. Front Surg 2022;9:862322.
72. Ueda D, Kakinuma T, Fujita S, Kamagata K, Fushimi Y, Ito R, *et al*. Fairness of artificial intelligence in healthcare: Review and recommendations. Jpn. J. Radiol. 2024;42:3-15.
73. Fletcher RR, Nakeshimana A, Olubeko O. Addressing fairness, bias, and appropriate use of artificial intelligence and machine learning in global health. Front Artif Intell 2021;3:561802.